Paper Details

  1. Home
  2. Paper Details

A randomized trial of melphalan and prednisone versus melphalan, prednisone, cyclophosphamide, MeCCNU, and vincristine in untreated multiple myeloma.

Author: CuruchetM, DragoskyM, GarayG, HubermanA B, LeinJ M, PalmerL, PavlovskyS, Quiroga-MicheoE, SaslavskyJ, Tezanos PintoM

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Research Support, U.S. Gov't, P.H.S.Research funding provided by the Public Health Service (PHS).

Overview

A study of 234 patients with multiple myeloma compared two treatment regimens: melphalan and prednisone (MP) versus MP plus cyclophosphamide, MeCCNU, and vincristine (MPCCV). While MPCCV showed a slightly higher response rate (70% vs 58%), the difference was not statistically significant. Similarly, the 48-month survival rates were comparable between the two groups (37% for MP and 39% for MPCCV). Both groups showed significant differences in survival based on disease stage (stage I 56%, stage II 46%, stage III 23%) and response to treatment (good response 68%, partial response 33%, no response 16%). Patients with higher creatinine levels had significantly lower survival rates (43% vs 27%). Overall, there was no significant difference in response rate or survival between the two treatment regimens.
Paper Details　
Original Abstract of the Article :
In a randomized study with 234 previously untreated patients with multiple myeloma, 129 were treated with melphalan (8 mg/m2 perorally for four days) and prednisone (40 mg/m2 perorally for seven days, both every four weeks) and 105 with melphalan and prednisone at the same doses plus cyclophosphamid...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1200/JCO.1984.2.7.836

データ提供：米国国立医学図書館（NLM）

Navigating the Shifting Sands of Multiple Myeloma Treatment

Multiple myeloma, a complex cancer of plasma cells, can feel like a desert of uncertainty for patients seeking effective treatment. This research explores two different treatment regimens for previously untreated multiple myeloma, aiming to find the most effective path through the shifting sands of this disease. The study compares the efficacy of melphalan and prednisone (MP) versus a more complex combination therapy (MPCCV), analyzing their impact on response rates and survival times.

Finding the Oasis of Success

The researchers found no significant difference in response rates or survival times between the two treatment regimens. This suggests that both MP and MPCCV can be effective in treating multiple myeloma, but the choice of treatment should be individualized based on patient factors. This is like discovering two oases in the desert, each offering unique benefits and challenges. The study's findings are encouraging, highlighting the importance of having multiple options available to patients.

Multiple Myeloma: A Journey Through the Desert

Multiple myeloma is a challenging disease, but the journey through the desert can be smoother with the right guidance. It's crucial to consult with a hematologist to develop a personalized treatment plan that aligns with your specific needs and goals. Remember, there are oases of hope and effective treatments available, and with the right support, you can navigate the sands of multiple myeloma with resilience and strength.

Dr. Camel's Conclusion

This research sheds light on the complexity of treating multiple myeloma. It highlights the importance of individualized care, tailored to each patient's unique circumstances. While the desert of multiple myeloma can be daunting, finding the right oasis of treatment can make the journey more manageable and hopeful. Remember, there are resources and support available to guide you through this challenging landscape.

Date :
  1. Date Completed 1984-08-23
  2. Date Revised 2017-02-10
Further Info :

Pubmed ID

6376722

DOI: Digital Object Identifier

10.1200/JCO.1984.2.7.836

Related Literature

Article Analysis
・Effective treatment of multiple myeloma
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.